Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 6/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.40 |
| ▸ | ABL1 | P00519 | 5/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.31 |
| ▸ | MERTK | Q12866 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10239939 | 0.88 | HCRTR1 (0.39) | HCRTR1HCRTR2AXLTYRO3MERTK | |
| SCHEMBL10241632 | 0.88 | HCRTR2 (0.43) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL10241607 | 0.81 | PKM (0.40) | HRH3 | |
| SCHEMBL2619069 | 0.79 | HCRTR1 (0.62) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL10188997 | 0.79 | HCRTR2 (0.65) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL2619180 | 0.78 | HCRTR1 (0.52) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL2619086 | 0.77 | HCRTR1 (0.51) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL10241205 | 0.75 | HCRTR2 (0.43) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL10241598 | 0.75 | HCRTR1 (0.35) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL10241669 | 0.75 | HCRTR1 (0.37) | HCRTR1HCRTR2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | HCRTR2, HCRTR1, CNR1 | HCRTR1 2/4885HCRTR2 1/4885ABL1 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.